A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC). Phase II trial of intravenous carboplatin (C), ...
Medicare covers bone density scans once every 2 years or more frequently if medically necessary. If you meet eligibility requirements and use a facility that accepts Medicare, there are no ...
Please provide your email address to receive an email when new articles are posted on . According to recently published results, there was no difference seen in clinical and radiologic outcomes with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results